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Introduction {#sec1}
============

Inhibitory neurotransmission in the spinal cord is shaped by the balance between GABA~A~ and glycine receptors that co-localize at the majority of synapses ([@bib6], [@bib8], [@bib44]) and that are activated by the co-release of the two neurotransmitters from presynaptic vesicles ([@bib1], [@bib18], [@bib39]). GABA~A~Rs and GlyRs bind to the same region of the synaptic scaffold protein gephyrin ([@bib20], [@bib22], [@bib27], [@bib45]), which is thought to create strong competition between the receptors for synaptic binding sites. As a consequence, the main parameters controlling receptor trapping at mixed inhibitory synapses are the number of receptors, the number of available binding sites, and the relative affinity of the receptors for these sites (discussed in [@bib41]). Plastic changes in the strength of receptor-gephyrin interactions are expected to shift the equilibrium between GABA~A~Rs and GlyRs and alter the functional profile of mixed inhibitory synapses.

Post-translational modifications of gephyrin regulate the clustering of the scaffold protein and hence the number of receptor binding sites at synapses ([@bib12]). Phosphorylation of amino acid residue S270 of gephyrin appears to be particularly important for the clustering of gephyrin at GABAergic synapses, causing a variety of changes in the number, size, and intensity of synaptic clusters ([@bib2], [@bib10], [@bib19], [@bib23], [@bib47], [@bib46]). The synaptic copy numbers of gephyrin and receptor complexes often change in synchrony owing to their reciprocal stabilization at synapses; however, it is unclear whether S270 phosphorylation acts on gephyrin oligomerization or on receptor-gephyrin binding ([@bib41]). From a mechanistic point of view, gephyrin is known to assume various conformational states ([@bib38]) that could mediate the downstream effects of S270 phosphorylation.

The intracellular domains (ICDs) of GABA~A~Rs and GlyRs are subject to post-translational modifications that target the receptors\' gephyrin-binding motifs ([@bib29], [@bib42]). It was recently shown that receptor-gephyrin interactions are also modulated by conformational changes associated with receptor activity ([@bib11], [@bib33]). These studies suggest that in addition to the primary interaction domains, the strength of receptor-gephyrin binding is controlled by mechanisms that are related to the channel function. To test this idea, we set out to investigate whether the cyclic AMP (cAMP)-dependent reduction of glycinergic transmission during inflammation ([@bib15]) is accompanied by changes in receptor mobility. We found that phosphorylation of GlyRα3 at amino acid residue S346 by protein kinase A (PKA) indeed disrupted receptor trapping at spinal cord synapses. Unexpectedly, we also identified a non-canonical cAMP signaling pathway that controls the phosphorylation status of gephyrin without affecting the size of gephyrin clusters and that leads to a specific reduction in GABA~A~R clustering. These observations lend support to the concept that diverging signaling processes downstream of cAMP differentially regulate GABA~A~R and GlyR numbers at mixed inhibitory synapses.

Results {#sec2}
=======

Reduction of GABA~A~R Levels at Spinal Cord Synapses by Forskolin {#sec2.1}
-----------------------------------------------------------------

To investigate the regulation of inhibitory synapses by cAMP-dependent mechanisms, we carried out immunocytochemical analysis of endogenous GlyRs, GABA~A~Rs, and the scaffold protein gephyrin in two-week-old dissociated rat spinal cord neurons. cAMP-dependent signaling was induced with 20 μM forskolin for 30 min, followed by fixation of the neurons and triple labeling with specific antibodies against GlyRα1, GABA~A~Rβ3, and gephyrin ([Figure 1](#fig1){ref-type="fig"}A). Quantification of the integrated fluorescence intensity of synaptic puncta did not reveal any significant differences of GlyR levels between control cultures treated with vehicle (0.2% ethanol, see [Methods](#sec4){ref-type="sec"} for details) and neurons exposed to forskolin ([Figure 1](#fig1){ref-type="fig"}B). We did, however, observe a strong reduction of both GABA~A~R and gephyrin immunoreactivity in response to forskolin treatment. The effect of forskolin was similar in magnitude for GABA~A~Rβ3 and gephyrin (p \> 0.05, ANOVA), with a mean reduction to 80.2% ± 2.8% and 76.6% ± 3.0% (mean ± SEM, not background corrected) of the control value, respectively, suggesting that the two effects could be linked ([Figure 1](#fig1){ref-type="fig"}B).Figure 1Forskolin Reduces GABA~A~R and Gephyrin Immunoreactivity at Spinal Cord Synapses(A) Triple immunolabeling of endogenous GlyRs, GABA~A~Rs, and gephyrin in cultured rat spinal cord neurons (DIV16). Cells were treated with 20 μM forskolin (For) or kept under control conditions for 30 min (Ctr; vehicle 0.2% ethanol), fixed, and stained with antibodies against the GlyRα1 and GABA~A~Rβ3 subunits, and with the rat gephyrin antibody mAb7a (Geph 7a, Synaptic Systems). Scale bar, 5 μm.(B) Quantification of the integrated fluorescence intensity at synaptic GlyR puncta in the three channels (cell-by-cell analysis, arbitrary units normalized to the control condition in each channel; data are represented as 10%, 25%, 50% (median), 75%, and 90% percentiles; the mean is indicated as a cross; n~Ctr~ = 86, n~For~ = 79 cells from 6 coverslips and 3 independent experiments; \*\*\*p \< 0.001, ANOVA).(C) Cumulative probability of the ratio of the GlyR (black traces) or GABA~A~R fluorescence intensities (red traces) relative to the Geph 7a immunoreactivity at synapses (control: solid lines, n~Ctr~ = 1.4 × 10^4^; forskolin: dotted lines, n~For~ = 1.2 × 10^4^ synapses).

Synapse-by-synapse analysis of the relative changes in receptor and gephyrin immunoreactivity confirmed that forskolin treatment had little effect on the GABA~A~Rβ3/gephyrin ratio ([Figure 1](#fig1){ref-type="fig"}C, red traces). However, the apparent increase in the GlyRα1/gephyrin ratio in the presence of forskolin (black dotted line) was difficult to interpret, given that gephyrin levels directly control the number of receptor-binding sites ([@bib43]). It appeared doubtful to us how GlyR levels could be maintained in the face of a 25% loss in the number of binding sites. One explanation could be that the internalized fraction of GlyRs is increased ([@bib4]), without changing the total fluorescence intensity at synapses. We therefore carried out live surface labeling of GlyRα1 ([Figure S1](#mmc1){ref-type="supplementary-material"}A). However, we did not observe any significant difference between the surface GlyRα1 levels in control conditions and after 30 min of 20 μM forskolin application ([Figure S1](#mmc1){ref-type="supplementary-material"}B).

Forskolin Alters mAb7a Immunoreactivity but Not the Total Gephyrin at Synapses {#sec2.2}
------------------------------------------------------------------------------

The monoclonal gephyrin antibody mAb7a that was used in the above experiments is widely employed to quantify gephyrin levels at inhibitory synapses, despite the fact that it recognizes an epitope in the central domain of gephyrin that includes the phosphorylated serine residue S270 ([@bib23]). To verify the observed reduction of gephyrin labeling after forskolin treatment we performed experiments with a different monoclonal antibody that binds to the gephyrin E-domain (3B11; [@bib40]). To our surprise, gephyrin immunoreactivity with the antibody 3B11 was not different in control and forskolin-treated neurons (p \> 0.05, ANOVA, [Figures 2](#fig2){ref-type="fig"}A and 2B), whereas mAb7a labeling was strongly reduced (55.3% ± 4.2% of control, mean ± SEM, p \< 0.001). Note that the data were corrected for the background, which explains the stronger reduction than in the previous experiment ([Figure 1](#fig1){ref-type="fig"}B, see methods for data analysis). Endogenous GlyRα1 labeling was not significantly different between the two conditions (p \> 0.05), in agreement with our earlier data.Figure 2Gephyrin Protein Levels at Synapses Are Not Altered by Forskolin(A) Sample images showing the effect of forskolin treatment on GlyRα1 (magenta in the merged image) and two different gephyrin antibodies (mAb7a and 3B11, green). Fluorescent signals from Geph 7a were reduced by forskolin, whereas GlyRα1 and Geph 3B11 were not affected. Scale bar, 5 μm.(B) Integrated fluorescence intensity of endogenous gephyrin at rat spinal cord synapses was quantified in GlyRα1-positive puncta (background-corrected data). Geph 7a labeling was decreased by 45% ± 4% after 30-min treatment with 20 μM forskolin (For) compared with the control (\*\*\*p \< 0.001, ANOVA), whereas no significant changes (NS) were observed with Geph 3B11 (GlyRα1: n~Ctr~ = 149, n~For~ = 144 cells, 5 experiments; Geph 7a: n~Ctr~ = 60, n~For~ = 56, 2 experiments; Geph 3B11: n~Ctr~ = 89, n~For~ = 88 cells, 3 experiments). Data are represented as 10%, 25%, 50%, 75%, and 90% percentiles; the mean is indicated as a cross.(C) Dissociated spinal cord cultures prepared from an mRFP-gephyrin knock-in mouse strain (mRFP-Geph KI, magenta) were treated with or without forskolin and then immunolabeled for GlyRα1 (green). Scale bar, 5 μm.(D) No significant change in mRFP-Geph KI fluorescence and GlyRα1 immunoreactivity was observed (n~Ctr~ = 39; n~For~ = 40 cells, 1 experiment).(E) Organotypic spinal cord cultures made from mRFP-gephyrin KI mice were treated at DIV21 with 20 μM forskolin for 60 min and fixed, labeled, and analyzed by confocal microscopy. Geph 7a immunoreactivity (green in merged image) and mRFP fluorescence (magenta) were quantified in a consecutive series of nine single-plane images taken from the dorsal edge of the slice toward the center (n~Ctr~ = 44, n~For~ = 57 images from 7--8 slices and 2 independent experiments; \*\*\*p \< 0.0001 for the pooled data points for each condition, t test; data are shown as mean ± SD). The sample images represent a non-treated control slice; the gray outline illustrates the shape of the complete organotypic slice. Scale bar, 100 μm; zoomed images, 5 μm.

These observations raised our suspicion that the reduction in gephyrin labeling could be due to the mAb7a antibody and did not reflect any real change in the total gephyrin amount at synapses. We tested this hypothesis in spinal cord cultures derived from a knock-in mouse strain that expresses endogenous mRFP-tagged gephryin ([@bib25]). Neither GlyRα1 nor the total mRFP-gephyrin levels at synapses were altered by bath application of forskolin ([Figures 2](#fig2){ref-type="fig"}C and 2D; p~GlyRα1~ \> 0.05, p~mRFP-Geph~ \> 0.05, ANOVA), confirming that the treatment did not have a noticeable effect on the gephyrin molecule numbers at synapses.

To directly compare the effects of forskolin on mAb7a immunoreactivity and total mRFP-gephyrin levels in a more integrated system, we also conducted experiments in organotypic slice cultures from knock-in animals. Three-week-old spinal cord slice cultures were treated with 20 μM forskolin for 60 min, fixed, immunolabeled, and analyzed with confocal microscopy ([Figure 2](#fig2){ref-type="fig"}E). The mAb7a and mRFP-gephyrin fluorescence at synapses was quantified in single image planes that were taken from the dorsal edge of the slice toward the central region. We observed that the ratio of mAb7a/mRFP-gephyrin was reduced after forskolin treatment across all regions, demonstrating that mAb7a immunoreactivity is systematically reduced in different neuronal populations, and is not representative of the total synaptic gephyrin levels in our experimental paradigm.

Forskolin Reduces Gephyrin Phosphorylation of Residue S270 {#sec2.3}
----------------------------------------------------------

On the molecular level, the reduction in mAb7a immunoreactivity could be due either to the de-phosphorylation of gephyrin at residue S270 and/or to conformational changes induced by forskolin that render the epitope inaccessible for the antibody. To distinguish between these possibilities, we analyzed the gephyrin phosphorylation status by Western blotting ([Figure 3](#fig3){ref-type="fig"}). Dissociated rat spinal cord cultures were kept in medium containing 20 μM forskolin for 30 min, total protein fractions were collected in the presence of phosphatase inhibitors, and samples were separated by SDS-PAGE. Western blot membranes were sequentially probed with mAb7a antibody and with 3B11 that served as a loading control for total gephyrin ([Figure 3](#fig3){ref-type="fig"}A, first two lanes). Quantification of the mAb7a/3B11 ratio showed that forskolin treatment reduces mAb7a immunoreactivity by about 50% compared with the control condition ([Figure 3](#fig3){ref-type="fig"}B). It should be noted, however, that the mAb7a antibody is not well suited for Western blotting and produces only weak chemiluminescence signals.Figure 3Forskolin Reduces Gephyrin Phosphorylation of Residue S270(A) Western blotting of total protein fractions of rat spinal cord cultures exposed to forskolin (For) or kept in control condition (Ctr). Sequential labeling of the membranes with the gephyrin antibodies mAb7a and 3B11 identified the endogenous protein (95 kDa) and lentivirus-expressed mEos4b-gephyrin (130 kDa).(B) For each Western blot membrane, we measured the intensity ratio of mAb7a/3B11 for all corresponding bands (endogenous gephyrin and recombinant mEos4b-gephyrin). Forskolin treatment reduced S270 phosphorylation of gephyrin by 45.8% as judged by the lower mAb7a/3B11 ratio (n = 9 bands per condition from 3 independent experiments, p \< 0.001, paired t test).

To confirm the identity of the detected 95-kDa bands, we repeated the same experiment using cultures that had been infected with lentivirus driving the expression of mEos4b-gephyrin. The detection of an additional band at 130 kDa in these samples demonstrates the specificity of the mAb7a antibody ([Figure 3](#fig3){ref-type="fig"}A, lanes 3 and 4). What is more, the signals of both bands were weaker in the forskolin-treated sample, showing that the phosphorylation of both endogenous gephyrin and recombinant mEos4b-gephyrin are reduced by forskolin ([Figure 3](#fig3){ref-type="fig"}B). Across both pairs of samples and three independent experiments, the reduction in mAb7a/3B11 ratio was highly significant (mean reduction 45.8%, p \< 0.001, paired t test, n = 9 bands per condition). These data indicate that forskolin treatment reduces S270 phosphorylation, although they do not exclude the fact that gephyrin could undergo concomitant conformational changes ([@bib38]).

PKA-Independent Effect of Forskolin on Gephyrin Phosphorylation {#sec2.4}
---------------------------------------------------------------

PKA is considered as the main effector downstream of cAMP signaling. To characterize the mechanism by which forskolin leads to the de-phosphorylation of residue S270 of gephyrin, we tested the involvement of known *in vivo* PKA phosphorylation sites of gephyrin. Wild-type mEos4b-gephyrin and a PKA-phosphorylation-deficient variant carrying the amino acid substitutions S294A/S295A/S303A/S305A/S319A (Eos4-Geph^PKA-^) were expressed in spinal cord neurons by lentivirus infection ([Figures 4](#fig4){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}C), and synaptic gephyrin levels were quantified after treatment of the neurons with forskolin for different durations (15, 30, 60 min).Figure 4PKA-Independent Effect of Forskolin on Gephyrin Phosphorylation(A) mEos4b-tagged wild-type (wt) and PKA-insensitive (PKA-) gephyrin were expressed in rat spinal cord neurons using lentiviral infection (green in merged image). Cells treated without (Ctr) or with forskolin (For) were labeled with Geph 7a antibody (magenta) and GlyRα1 antibody (shown in [Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). Scale bar, 5 μm.(B) Time course of the ratio of Geph 7a/Eos4-Geph fluorescence intensity (normalized for each construct to the control condition in each experiment) after forskolin application of up to 60 min (n \> 40 cells for each construct and time point from 2 experiments, \*\*\*p \< 0.001 against control, KW test).(C) After 30-min exposure to forskolin, the Geph 7a/Eos4-Geph ratio was consistently reduced, regardless of the presence of the PKA inhibitor H-89 (n = 60 cells per condition, 2 experiments, \*\*\*p \< 0.001 against control, ANOVA).(D) Triple immunostaining of GlyRα1, Geph 7a, and GABA~A~Rβ3 with or without the EPAC agonist 007 for 30 min. Scale bar, 5 μm.(E) Normalized fluorescence intensity of 007-treated neurons (n~Ctr~ = 90, n~007~ = 83 cells from 3 experiments). EPAC activity significantly reduced Geph 7a and GABA~A~Rβ3 labeling, but not GlyRα1 (\*\*p \< 0.01, ANOVA).(F and G) Spinal cord neurons were treated for 30 min with forskolin and H-89 in the presence or absence of 40 nM okadaic acid (Oka). Blockade of phosphatase PP1/PP2A increased the Geph 7a signal (magenta), but not Geph 3B11 (green), at the synapses (n~For/H89~ = 86 and n~For/H89+Oka~ = 84 cells from 3 experiments, \*\*\*p \< 0.001, t test). Scale bar, 5 μm. Data are represented as 10%, 25%, 50%, 75%, and 90% percentiles; the mean is indicated as a cross.

Immunolabeling with mAb7a antibody confirmed that S270 phosphorylation was decreased relative to the total Eos4-Geph^wt^ levels at synapses (mAb7a/Eos4 ratio, p \< 0.001 at all time points versus control, Kruskal-Wallis (KW) test; [Figure 4](#fig4){ref-type="fig"}B, see also [Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). Surprisingly, Eos4-Geph^PKA-^-expressing neurons showed the same temporal profile, suggesting that forskolin did not act directly via any of the mutated PKA phosphorylation sites. We also applied forskolin together with the PKA inhibitor H-89 ([Figure 4](#fig4){ref-type="fig"}C). The mAb7a labeling was reduced to a similar level as in Eos4-Geph^wt^-expressing neurons treated with forskolin without H-89 (p \> 0.05, ANOVA). Therefore the effect of forskolin on gephyrin phosphorylation did not appear to be mediated by PKA.

We then considered the involvement of other cAMP-dependent signaling proteins, namely, the exchange proteins directly activated by cAMP (EPAC). Immunolabeling of EPAC shows a punctate distribution in spinal cord neurons that partially overlaps with gephyrin clusters ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Co-expression of N- and C-terminally tagged EPAC2 together with mRFP-gephyrin substantiated the presence of EPAC at inhibitory synapses ([Figure S2](#mmc1){ref-type="supplementary-material"}C). The EPAC-specific agonist 007-AM led to a reduction of mAb7a labeling of endogenous gephyrin and of β3-containing GABA~A~Rs (p \< 0.01, ANOVA), but did not have any effect on GlyRα1 levels ([Figures 4](#fig4){ref-type="fig"}D and 4E). These effects were very similar to what had been observed with forskolin ([Figure 1](#fig1){ref-type="fig"}B). Together, the results indicate that EPAC and not PKA is responsible for the changes in gephyrin phosphorylation.

As EPAC has been reported to form a complex and act in concert with protein phosphatase PP2a ([@bib16]), we treated cells for 15 min with or without 40 nM okadaic acid, an inhibitor of PP1/PP2a, and then added forskolin together with H-89 for further 30 min ([Figures 4](#fig4){ref-type="fig"}F and 4G). Okadaic acid reversed the forskolin effect, resulting in a significant increase in mAb7a, but not 3B11, labeling (p~mAb7a~ \< 0.001, p~3B11~ = 0.20, t test). This is in agreement with an earlier study that has implicated PP1/PP2a in the de-phosphorylation of gephyrin at position S270 ([@bib19]).

Single Molecule Localization Microscopy of Synaptic Gephyrin Clusters {#sec2.5}
---------------------------------------------------------------------

To explore the downstream consequences of S270 de-phosphorylation on the organization of the gephyrin scaffold at inhibitory synapses, we did super-resolution single-molecule localization microscopy (SMLM) imaging of recombinant gephyrin tagged with the photoconvertible protein mEos4b in fixed spinal cord neurons ([Figure 5](#fig5){ref-type="fig"}A). Owing to the high spatial resolution of the technique, differences in the ultrastructure of the synapse and in the distribution of scaffold proteins can be identified on the nanometer scale. As judged from pointillist images of the single fluorophore detections, Eos4-Geph^wt^ is densely packed in synaptic clusters along the dendrites and on the somata of infected neurons. These clusters can be easily distinguished by their size and the number of detections from non-synaptic gephyrin molecules that are diffusely distributed throughout the cell ([Figure 5](#fig5){ref-type="fig"}A, arrowheads).Figure 5SMLM Super-resolution Imaging of Synaptic Gephyrin Clusters(A) Single molecule detections (shown as black dots, or blue in the zoomed images) of recombinant mEos4b-gephyrin expressed in spinal cord neurons in control condition (Ctr) or after forskolin application (For). Arrowheads indicate the positions of small, non-synaptic clusters arising from the repetitive detection of single mEos4b fluorophores. Dense synaptic clusters were identified based on cluster size and detection number in the pointillist images (yellow areas in the zoomed images, see [Methods](#sec4){ref-type="sec"}). Clusters with less than 200 detections were not considered (green areas). Scale bar, 1 μm; insert, 100 nm.(B) Quantification of synaptic cluster areas, detection numbers, and detection densities (n~Ctr~ = 1,237, n~For~ = 894 clusters from 32 cells per condition and 3 independent experiments, \*p \< 0.05, MW test).(C) dSTORM imaging of endogenous gephyrin labeled with mAb7a and secondary Alexa Fluor 647-coupled antibodies. Cluster analysis was done as in (A), with a lower threshold of 50 detections per cluster. Scale bar, 1 μm; insert, 100 nm.(D) Quantification of the cluster area and the number of Alexa 647 detections shows a correlated decrease in the forskolin-treated neurons compared with control cells (n~Ctr~ = 8,162 clusters in 69 cells, n~For~ = 7,010 clusters in 68 cells, 3 experiments, \*\*\*p \< 0.001, MW test). Data are shown as 10%, 25%, 50%, 75%, and 90% percentiles and the mean (cross).

The quantification of gephyrin cluster sizes did not reveal any differences between control and forskolin-treated neurons (synapse-by-synapse analysis, median area~Ctr~: 0.041 μm^2^, area~For~: 0.042 μm^2^, p = 0.20, Mann-Whitney U-test \[MW\] test). Similarly, the number of mEos4b detections per cluster was not altered ([Figure 5](#fig5){ref-type="fig"}B). These data show that forskolin treatment did not affect the clustering of gephyrin molecules at synapses. The fact that the number of detections was the same in both experimental conditions was expected, because the mEos4b detections reflect the total gephyrin content of the synapse. Due to the large sample size (n \> 800 synapses per condition), there was a significant difference in the detection density ([Figure 5](#fig5){ref-type="fig"}B, right panel). However, cell-by-cell analysis of the same data did not reveal any obvious difference of the absolute detection densities ([Figure S3](#mmc1){ref-type="supplementary-material"}A).

Experiments were also carried out using dSTORM to identify changes in the distribution of phosphorylated pS270-gephyrin ([Figure 5](#fig5){ref-type="fig"}C). Here, endogenous gephyrin in fixed spinal cord neurons was labeled with mAb7a and Alexa Fluor 647-coupled secondary antibodies. Pointillist images of Alexa 647 detections were analyzed in the same way as the mEos4b images, but with an adjusted threshold for cluster detection (see [Methods](#sec4){ref-type="sec"}). Both cluster size and detection numbers showed a significant reduction after forskolin treatment (median area~control~: 0.018 μm^2^, area~forskolin~: 0.014 μm^2^, p \< 0.001, MW test, see [Table S2](#mmc1){ref-type="supplementary-material"}). Interestingly, the detection density of pS270-gephyrin clusters was not noticeably changed by forskolin ([Figures 5](#fig5){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}B). Our interpretation of these data is that the de-phosphorylation of gephyrin occurs within specific sub-synaptic domains, but that it has no influence on the overall organization of the gephyrin scaffold.

cAMP-Dependent Regulation of GABA~A~R Diffusion {#sec2.6}
-----------------------------------------------

As the S270 phosphorylation status did not appear to have any effect on gephyrin clustering as such, we explored possible consequences of S270 de-phosphorylation on receptor binding at synapses. Single particle tracking with quantum dots was carried out in infected rat spinal cord neurons expressing different Dendra2-tagged receptor subunits. Diffusion coefficients were calculated from receptor trajectories at synapses as well as in the extrasynaptic plasma membrane ([Figure 6](#fig6){ref-type="fig"}A).Figure 6cAMP-Dependent Regulation of GABA~A~R and GlyR Diffusion(A) Quantum dot (QD) trajectories of Dendra2-GABA~A~Rγ2-containing receptor complexes (red traces) in control neurons and in the presence of either forskolin or 007-AM. Synapses were identified with FM4-64 labeling (white areas). Scale bar, 5 μm.(B) Cumulative probabilities of QD-tagged Dendra2-GABA~A~Rγ2 diffusion coefficients at synapses in the three experimental conditions (median D values: D~Ctr~ = 0.0022 μm^2^/s, D~For~ = 0.0031, D~007~ = 0.0028, n~Ctr~ = 730 trajectories from 41 cells, n~For~ = 318 trajectories from 42 cells, n~007~ = 384 trajectories from 40 cells, 7 coverslips per condition, 3 experiments).(C) The median diffusion coefficients of Dendra2-GlyRα1 at spinal cord synapses were similar in the control and forskolin condition (in the absence of the drug, after a 30-min forskolin incubation; D~Ctr~ = 0.0083 μm^2^/s, D~For~ = 0.0076, n \> 1,000 trajectories from 5 experiments).(D) Synaptic diffusion coefficients of Dendra2-GlyRα3L and α3K splice variants. Forskolin application specifically increased the speed of diffusion of Dendra2-GlyRα3L at synapses (α3L: D~Ctr~ = 0.0041, D~For~ = 0.0058, n \> 1,000; α3K: D~Ctr~ = 0.0060 μm^2^/s, D~For~ = 0.0066, n \> 900 QD trajectories; 5 experiments).(E) Model of cAMP-dependent pathways regulating inhibitory receptor dynamics at mixed spinal cord synapses, including the pharmacological agents used in this study (see text for details).

In the presence of forskolin, the diffusion of Dendra2-GABA~A~Rγ2 receptors at synapses was considerably faster compared with control neurons ([Figure 6](#fig6){ref-type="fig"}B; p \< 0.001, KW test). The same was true for neurons treated with the EPAC agonist 007-AM (p \< 0.001). In contrast, we did not observe any changes in the diffusion of GlyRα1-containing receptors following a 30-min exposure to forskolin ([Figure 6](#fig6){ref-type="fig"}C). These data indicate that cAMP-dependent signaling via EPAC acts specifically on GABA~A~R-gephyrin binding, which is reflected in an increased mobility of the receptor at synapses.

Neurons in the dorsal horn of the spinal cord relay nociceptive signals from primary sensory neurons to the brain. The release of prostaglandin E~2~ (PGE~2~) during inflammation leads to the central disinhibition of the nociceptive pathways by blocking GlyRα3-containing receptor complexes in a PKA-dependent manner ([@bib15]). Given the known regulation of GlyRα3 by PKA in the context of inflammatory pain, we therefore looked at receptor diffusion in neurons expressing the splice variants Dendra2-GlyRα3L and α3K. The variant GlyRα3L contains a 15-amino acid insertion in the proximity of the PKA phosphorylation site S346 ([@bib15], [@bib31]). The mobility of GlyRα3K-containing receptors was not changed, whereas the GlyRα3L variant was accelerated significantly after forskolin application (p \< 0.001, KW test; [Figure 6](#fig6){ref-type="fig"}D), suggesting that forskolin weakened the gephyrin binding of GlyRα3L-containing receptor complexes. This fits with immunocytochemical data that showed a reduction of Dendra2-GlyRα3L levels at synapses in response to forskolin ([Figure S4](#mmc1){ref-type="supplementary-material"}). Moreover, mutagenesis of GlyRα3L at position S346 abolished the PKA-dependent reduction of synaptic receptor levels ([Figure S5](#mmc1){ref-type="supplementary-material"}). In conclusion, separate cAMP pathways act on GABA~A~Rs and GlyRα3L/β complexes at mixed inhibitory synapses through post-translational modifications targeting gephyrin as well as individual receptor subtypes ([Figure 6](#fig6){ref-type="fig"}E).

Discussion {#sec3}
==========

The main result of this study is that cAMP-dependent EPAC signaling reduces gephyrin phosphorylation at the amino acid residue S270, weakening the GABA~A~R-gephyrin interaction and leading to the selective dispersal of GABA~A~Rs from mixed inhibitory synapses in spinal cord neurons.

Gephyrin Clustering and the Role of S270 Phosphorylation {#sec3.1}
--------------------------------------------------------

Labeling of gephyrin with the widely used antibody mAb7a showed that immunoreactivity of synaptic gephyrin clusters was substantially reduced in response to forskolin. As the antibody is specific for an epitope that includes the phosphorylated residue S270 of gephyrin ([@bib23]), these data indicated that forskolin treatment causes a marked change in the phosphorylation status of endogenous and recombinant gephyrin in cultured spinal cord neurons as well as in organotypic slices.

The phosphorylation of gephyrin at residue S270 has been implicated in the regulation of gephyrin clustering at GABAergic synapses ([@bib12]). Several studies suggested that the phosphorylation-deficient gephyrin variant S270A gives rise to a higher number ([@bib47], [@bib46]) or greater intensity and size of synaptic gephyrin clusters ([@bib2]). We did not observe any significant changes in the total synaptic gephyrin levels, suggesting that S270 phosphorylation does not affect gephyrin clustering as such. This is consistent with the data of Kuhse and colleagues, who did not see any obvious changes of gephyrin clustering by S270 de-phosphorylation following the inhibition of Cdk5 ([@bib19], [@bib23]).

Moreover, we did not detect any ultrastructural changes of the synaptic gephyrin scaffold using SMLM of mEos4b-tagged gephyrin in spinal cord cultures treated with forskolin. Endogenous pS270-gephyrin occupied a smaller synaptic area than total Eos4-Geph^wt^ as judged by dSTORM imaging. Upon forskolin treatment, the pS270 area was further reduced, whereas the detection density remained unchanged. These data are at odds with the observed differences in the density of phosphorylation variants of gephyrin that were overexpressed in primary hippocampal neurons ([@bib2]). Even though the overall clustering of gephyrin was not dependent on its phosphorylation, our super-resolution images suggest that the pS270 form is concentrated in specialized sub-synaptic domains ([@bib34]). However, it cannot be ruled out that these results are influenced by the stochasticity of dSTORM imaging ([@bib49]).

A possible explanation for the conflicting findings is that gephyrin residue S270 is the target of converging signaling pathways, which means that its phosphorylation could involve additional, as yet unidentified post-translational modifications. After all, gephyrin contains more than 50 known *in vivo* modifications (see PhosphoSitePlus database, [www.phosphosite.org](http://www.phosphosite.org){#intref0010}; [@bib17]). For example, the phosphorylation of S268 by ERK1/2 ([@bib46]), SUMOylation, or acetylation of gephyrin ([@bib10]) could shape the responses downstream of S270 phosphorylation. In our experiments, the silencing of multiple putative PKA sites of gephyrin (including residues S303 and S305; [@bib7]) did not induce any changes in cluster intensity (I~Geph\ PKA~- = 1.001 ± 0.087 of the wild-type construct, mean ± SEM, n = 42 cells, 2 experiments), ruling out that the phosphorylation of these sites by PKA could have counteracted an effect of pS270 on gephyrin clustering.

We therefore conclude that S270 phosphorylation does not regulate gephyrin clustering, that is to say that it has no effect on gephyrin-gephyrin binding. Instead, our data point to a model whereby S270 phosphorylation promotes the GABA~A~R-gephyrin interaction ([Figure 6](#fig6){ref-type="fig"}E). This is in line with the loss of GABA~A~R clustering in response to S270 de-phosphorylation after Cdk5 inhibition ([@bib19]). The mobilization of GABA~A~Rs does not have major structural consequences at mixed inhibitory synapses in the spinal cord, where GlyR-gephyrin interactions maintain the stability of the synaptic scaffold. In contrast, GABA~A~R dispersal is followed by a rapid loss of gephyrin at purely GABAergic synapses owing to the reciprocal stabilization of receptors and scaffold proteins (e.g., [@bib32]). A higher fraction of pS270 may also explain how synaptic GABA~A~R levels can be maintained during long-term application of diazepam, despite a substantial reduction in total gephyrin content ([@bib24]). In our view, this model can therefore reconcile some of the variable experimental results that have been reported.

Independence of GABA~A~R and GlyR Binding at Mixed Inhibitory Synapses {#sec3.2}
----------------------------------------------------------------------

The reduction of GABA~A~R-gephyrin binding by pS270 de-phosphorylation is remarkable in that it regulates receptor diffusion in a subtype-specific manner by targeting the gephyrin scaffold itself. Post-translational modifications of the ICDs of GABA~A~Rs and GlyRs have been shown to control the strength of individual receptor-gephyrin interactions ([@bib29], [@bib35], [@bib42]). As the inhibitory receptors bind to overlapping sites of gephyrin ([@bib27], [@bib45]) they directly compete for synaptic binding sites. This is exemplified by the opposite changes of α2- versus α5-containing GABA~A~R dynamics at hippocampal synapses ([@bib9]), where the reduction in the affinity of one receptor type allows another receptor to occupy the liberated binding sites.

The fact that forskolin treatment specifically interfered with the clustering of GABA~A~Rs (and GlyRα3) at synapses, but did not affect GlyRα1, shows that receptor levels can also be regulated separately, without prompting a compensatory effect ([Figure 6](#fig6){ref-type="fig"}E). Long-term blockade of network activity by tetrodotoxin likewise reduced GABA~A~R levels independently of GlyRs ([@bib43]). These observations imply that there is only a limited direct competition between receptors at mixed inhibitory synapses. Given the non-identity of the gephyrin-binding motifs (e.g., [@bib13], [@bib22], [@bib26]), it is feasible that S270 de-phosphorylation and potentially associated conformational changes could only affect the binding of certain receptor subtypes. This raises the new concept that the synaptic gephyrin scaffold displays distinct, receptor-specific binding modes.

If different receptors can be regulated independently from one another, what then is the fate of the liberated binding sites? Although we cannot exclude that GABA~A~Rs with a different subunit composition replace the β3-containing receptors, the most likely explanation is that the excessive binding sites are lost over time through the dissociation of gephyrin molecules from the synaptic cluster. This is consistent with the observation of a delayed reduction in mEos4b-gephyrin levels during long forskolin applications ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). There was also a trend that GlyRs decline after prolonged exposure to forskolin, suggesting that S270 de-phosphorylation could possibly affect GlyR-gephyrin binding. In view of the high affinity of the GlyRβ-gephyrin interaction, however, these processes are expected to take place on a much longer timescale and to a lesser degree ([@bib41]).

Another possibility for the relative independence of GABA~A~R clustering is the implication of alternative binding mechanisms. GABA~A~Rγ2-containing receptors, for instance, can be recruited by neuroligin-2 via Lhfpl4 binding ([@bib5], [@bib48]). The slight mismatch in the relative changes of GABA~A~Rs and pS270 levels ([Figure 1](#fig1){ref-type="fig"}C, red traces) could indeed point to the existence of a gephyrin-independent mechanism. Yet the overall correspondence between GABA~A~R and S270 phosphorylation levels suggests that GABA~A~R clustering at mixed inhibitory synapses in spinal cord neurons relies predominantly on a gephyrin-related mechanism.

Integration of cAMP-Dependent Pathways Regulating Receptor Trapping at Synapses {#sec3.3}
-------------------------------------------------------------------------------

The effect of forskolin on GABA~A~R diffusion at synapses led us to assume initially that the mechanism would be dependent on protein kinase A. There is ample evidence that PKA-dependent phosphorylation regulates GABA~A~R function and trafficking, often producing divergent effects (reviewed in [@bib30]). Unexpectedly, we found that neither mutagenesis of PKA phosphorylation sites of gephyrin nor the PKA blocker H-89 inhibited pS270 de-phosphorylation and GABA~A~R dispersal. It turned out that the GABA~A~R loss was in fact caused by a different process, namely, the activation of EPAC ([@bib37]). The presence of this cAMP-regulated guanine nucleotide exchange factor at inhibitory synapses ([Figure S2](#mmc1){ref-type="supplementary-material"}) acting in parallel to PKA could have an important role in the regulation of inhibitory neurotransmission. In other words, cAMP could simultaneously trigger PKA and EPAC signaling processes, leading to complex downstream effects at inhibitory synapses.

For instance, PGE~2~ is known to inhibit glycinergic currents in a PKA-dependent manner during inflammatory pain ([@bib15]). The GlyRα3 specificity of this effect comes from the presence of a PKA phosphorylation site at residue S346 in the ICD that is not present in GlyRα1. Phosphorylation of this site was shown to induce global conformational changes that extend to the agonist-binding pocket ([@bib14]). We found that forskolin treatment of Dendra2-GlyRα3L-expressing spinal cord neurons increased the mobility of the receptors, whereas no change was observed for GlyRα1. This suggests that changes in receptor-scaffold interaction parallel the changes in receptor activity ([@bib15], [@bib36]). In other words, the PKA-dependent inhibition of α3-containing GlyRs is associated with a weakening of the receptor-gephyrin interaction, lending further support to the hypothesis that the α-subunits of the GlyR can influence the strength of GlyRβ-gephyrin binding ([@bib33]).

In addition, GABA~A~Rβ subunits contain conserved PKA sites in their ICDs, the phosphorylation of which regulates GABA~A~R function ([@bib28]), internalization ([@bib21]), and possibly gephyrin binding ([@bib3], [@bib22]). How these different signaling processes are integrated at mixed inhibitory synapses is not yet understood. Nonetheless, our data demonstrate that cAMP signaling has a significant impact on the trapping of GABA~A~Rγ2- and GlyRα3L-containing receptors ([Figure 6](#fig6){ref-type="fig"}E). Given that α1-containing GlyRs cannot compensate for this loss, a reduction of inhibitory neurotransmission seems inevitable. The dispersal of GABA~A~Rs is likely to shift the inhibitory phenotype from a mixed to a purely glycinergic profile, with a fast, monophasic decay and lower charge transfer ([@bib1]). This effect could exacerbate the disinhibition observed during pathological processes such as inflammatory pain. On a more positive note, the independence of GABA~A~R and GlyR regulation may also enable the development of specific pharmacological approaches that promote functional compensation.

Limitations of the Study {#sec3.4}
------------------------

Different regulatory processes at inhibitory synapses may engage multiple and overlapping phosphorylation sites in the central domain of gephyrin. The phospho-specific antibody mAb7a therefore has to be seen as a sensitive tool that reports on one of these modifications that could be implicated in several regulatory mechanisms with different downstream consequences. This also raises concerns about the use of mAb7a antibody as a synaptic marker.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

The raw data of this article are available from the corresponding author upon request.
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Document S1. Transparent Methods, Figures S1--S5, and Tables S1 and S2
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